FI4335511T3 - Pienimolekyylinen normaalien ja kasvainsolujen trail-geenin indusointi syöpähoitona - Google Patents

Pienimolekyylinen normaalien ja kasvainsolujen trail-geenin indusointi syöpähoitona

Info

Publication number
FI4335511T3
FI4335511T3 FIEP23206770.2T FI23206770T FI4335511T3 FI 4335511 T3 FI4335511 T3 FI 4335511T3 FI 23206770 T FI23206770 T FI 23206770T FI 4335511 T3 FI4335511 T3 FI 4335511T3
Authority
FI
Finland
Prior art keywords
compound
use according
cancer
therapeutic agent
anticancer drug
Prior art date
Application number
FIEP23206770.2T
Other languages
English (en)
Finnish (fi)
Inventor
Wafik El-Deiry
Joshua E Allen
Gen Sheng Wu
Original Assignee
Penn State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47068061&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI4335511(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Penn State Res Found filed Critical Penn State Res Found
Application granted granted Critical
Publication of FI4335511T3 publication Critical patent/FI4335511T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FIEP23206770.2T 2011-04-29 2012-04-30 Pienimolekyylinen normaalien ja kasvainsolujen trail-geenin indusointi syöpähoitona FI4335511T3 (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161480743P 2011-04-29 2011-04-29

Publications (1)

Publication Number Publication Date
FI4335511T3 true FI4335511T3 (fi) 2026-01-29

Family

ID=47068061

Family Applications (2)

Application Number Title Priority Date Filing Date
FIEP23206770.2T FI4335511T3 (fi) 2011-04-29 2012-04-30 Pienimolekyylinen normaalien ja kasvainsolujen trail-geenin indusointi syöpähoitona
FIEP20152317.2T FI3679934T3 (fi) 2011-04-29 2012-04-30 Pienimolekyylinen normaalien ja kasvainsolujen TRAIL-geenin indusointi syöpähoitona

Family Applications After (1)

Application Number Title Priority Date Filing Date
FIEP20152317.2T FI3679934T3 (fi) 2011-04-29 2012-04-30 Pienimolekyylinen normaalien ja kasvainsolujen TRAIL-geenin indusointi syöpähoitona

Country Status (18)

Country Link
US (9) US8673923B2 (https=)
EP (4) EP3679934B1 (https=)
JP (7) JP6132833B2 (https=)
CA (1) CA2832342C (https=)
CY (1) CY1123010T1 (https=)
DK (3) DK3679934T3 (https=)
ES (3) ES2992934T3 (https=)
FI (2) FI4335511T3 (https=)
HR (3) HRP20200636T1 (https=)
HU (2) HUE049207T2 (https=)
LT (3) LT3679934T (https=)
MX (2) MX365365B (https=)
PL (3) PL2701708T3 (https=)
PT (3) PT4335511T (https=)
RS (3) RS65813B1 (https=)
SI (3) SI4335511T1 (https=)
SM (3) SMT202600075T1 (https=)
WO (1) WO2012149546A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI4335511T3 (fi) 2011-04-29 2026-01-29 Penn State Res Found Pienimolekyylinen normaalien ja kasvainsolujen trail-geenin indusointi syöpähoitona
US10314594B2 (en) 2012-12-14 2019-06-11 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10307167B2 (en) 2012-12-14 2019-06-04 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10813630B2 (en) 2011-08-09 2020-10-27 Corquest Medical, Inc. Closure system for atrial wall
US20140142689A1 (en) 2012-11-21 2014-05-22 Didier De Canniere Device and method of treating heart valve malfunction
WO2015073072A1 (en) * 2013-11-15 2015-05-21 Oncoceutics, Inc. 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
US9376437B2 (en) 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
US9688679B2 (en) 2013-03-13 2017-06-27 Oncoceutics, Inc. 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy
WO2014160130A1 (en) * 2013-03-13 2014-10-02 Oncoceutics, Inc. Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one
IL311202A (en) 2013-11-15 2024-05-01 Oncoceutics Inc 7-Benzyl-4-(2-methylbenzyl)-2, 4, 6, 7, 8, 9-hexahydroimidazo [1,2-A] pyrido[3,4-E] pyrimidine-5(1H)one, its salts and methods Use
US9566443B2 (en) 2013-11-26 2017-02-14 Corquest Medical, Inc. System for treating heart valve malfunction including mitral regurgitation
US11299528B2 (en) 2014-03-11 2022-04-12 D&D Pharmatech Inc. Long acting TRAIL receptor agonists for treatment of autoimmune diseases
LT3662910T (lt) 2014-03-31 2024-12-27 The Scripps Research Institute Trail geno indukcijai skirtas farmakoforas
US10842626B2 (en) 2014-12-09 2020-11-24 Didier De Canniere Intracardiac device to correct mitral regurgitation
WO2016123571A1 (en) 2015-01-30 2016-08-04 Oncoceutics Inc. 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, analogs and salts thereof and their use in therapy
JP2018510005A (ja) 2015-03-31 2018-04-12 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 幹細胞の送達媒体およびその使用
CN104860948B (zh) 2015-05-15 2017-09-26 南京盖特医药技术有限公司 咪唑并嘧啶酮类化合物及其制备方法和应用
WO2017106627A1 (en) 2015-12-17 2017-06-22 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
PL3408298T3 (pl) 2016-01-29 2025-03-31 Oncoceutics, Inc. Modulacja przez imiprydony receptora sprzężonego z białkiem g (gpcr)
KR102508650B1 (ko) 2016-04-07 2023-03-13 더 존스 홉킨스 유니버시티 사멸 수용체 작용제로써 췌장암 및 통증을 치료하기 위한 조성물 및 방법
US10172862B2 (en) 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas
US11767353B2 (en) 2020-06-05 2023-09-26 Theraly Fibrosis, Inc. Trail compositions with reduced immunogenicity
WO2024030645A1 (en) 2022-08-05 2024-02-08 Chimerix, Inc. Pharmaceutical compositions and uses thereof for the treatment of glioma
WO2024102447A1 (en) * 2022-11-10 2024-05-16 Emory University Uses of hydroimidazopyridopyrimidinone derivatives for managing aneurysms or other vascular conditions or diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA105008A (en) 1907-02-06 1907-04-30 Charles B. Grimshaw Self-closing valve
DE2150062A1 (de) * 1971-10-07 1973-04-12 Boehringer Sohn Ingelheim Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung
GB9407386D0 (en) 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
US5648097A (en) 1995-10-04 1997-07-15 Biotek, Inc. Calcium mineral-based microparticles and method for the production thereof
US6391336B1 (en) 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
ES2357225T3 (es) * 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.
AU2002367172A1 (en) 2001-12-21 2003-07-15 Bayer Pharmaceuticals Corporation 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
US20070141066A1 (en) * 2005-12-16 2007-06-21 Genentech, Inc. Method for Diagnosing, Prognosing and Treating Glioma
US8084027B2 (en) * 2006-02-10 2011-12-27 Nerviano Medical Sciences S.R.L. Combinations comprising a CDK inhibitor and a growth factor antibody or anti-mitotic
CA2656393A1 (en) 2006-06-30 2008-01-10 Schering Corporation Method of using substituted piperidines that increase p53 activity
WO2010009985A2 (en) * 2008-07-24 2010-01-28 Nerviano Medical Sciences S.R.L. Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents
CA2766322A1 (en) * 2009-06-24 2010-12-29 Stephen Evans-Freke Methods of using corticotropin-releasing factor for the treatment of cancer
FI4335511T3 (fi) 2011-04-29 2026-01-29 Penn State Res Found Pienimolekyylinen normaalien ja kasvainsolujen trail-geenin indusointi syöpähoitona
WO2014160130A1 (en) 2013-03-13 2014-10-02 Oncoceutics, Inc. Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one

Also Published As

Publication number Publication date
HRP20200636T1 (hr) 2020-07-10
SMT202400421T1 (it) 2024-11-15
EP4706682A2 (en) 2026-03-11
SI2701708T1 (sl) 2020-07-31
US9072744B1 (en) 2015-07-07
ES3063552T3 (en) 2026-04-17
JP2014514326A (ja) 2014-06-19
RS67757B1 (sr) 2026-03-31
ES2992934T3 (en) 2024-12-19
JP7600286B2 (ja) 2024-12-16
EP2701708A2 (en) 2014-03-05
JP6132833B2 (ja) 2017-05-24
US20220288079A1 (en) 2022-09-15
EP3679934A1 (en) 2020-07-15
PL4335511T3 (pl) 2026-03-30
EP4335511B1 (en) 2025-11-26
MX2019006379A (es) 2019-09-04
SMT202000272T1 (it) 2020-07-08
US20240415841A1 (en) 2024-12-19
CY1123010T1 (el) 2021-10-29
US9629842B2 (en) 2017-04-25
HRP20260228T1 (hr) 2026-03-27
PT4335511T (pt) 2026-02-20
HUE068623T2 (hu) 2025-01-28
US20170224690A1 (en) 2017-08-10
US20170000790A1 (en) 2017-01-05
MX2013012346A (es) 2014-08-22
SMT202600075T1 (it) 2026-03-09
EP3679934B1 (en) 2024-06-05
PL2701708T3 (pl) 2020-11-02
PL3679934T3 (pl) 2025-01-07
EP2701708A4 (en) 2015-01-07
US20120276088A1 (en) 2012-11-01
US12036223B2 (en) 2024-07-16
JP2024051080A (ja) 2024-04-10
EP2701708B1 (en) 2020-01-22
JP2019019145A (ja) 2019-02-07
DK2701708T3 (da) 2020-04-27
US20150202206A1 (en) 2015-07-23
HUE049207T2 (hu) 2020-09-28
WO2012149546A3 (en) 2013-01-03
RS65813B1 (sr) 2024-08-30
DK4335511T3 (da) 2026-02-02
MX365365B (es) 2019-05-30
LT4335511T (lt) 2026-02-25
JP2025159099A (ja) 2025-10-17
FI3679934T3 (fi) 2024-07-08
WO2012149546A2 (en) 2012-11-01
EP4335511A3 (en) 2024-05-15
HRP20241214T1 (hr) 2024-11-22
PT3679934T (pt) 2024-09-05
LT3679934T (lt) 2024-11-11
CA2832342C (en) 2019-12-31
CA2832342A1 (en) 2012-11-01
LT2701708T (lt) 2020-05-25
US20150265619A1 (en) 2015-09-24
SI4335511T1 (sl) 2026-03-31
EP4335511A2 (en) 2024-03-13
JP2023060196A (ja) 2023-04-27
MX379539B (es) 2025-03-11
DK3679934T3 (en) 2024-07-22
US20140248264A1 (en) 2014-09-04
JP2021185210A (ja) 2021-12-09
US8673923B2 (en) 2014-03-18
ES2786033T3 (es) 2020-10-08
JP2016199580A (ja) 2016-12-01
US9452165B2 (en) 2016-09-27
SI3679934T1 (sl) 2025-04-30
USRE46290E1 (en) 2017-01-31
PT2701708T (pt) 2020-05-08
RS60186B1 (sr) 2020-06-30
US9061032B2 (en) 2015-06-23

Similar Documents

Publication Publication Date Title
FI4335511T3 (fi) Pienimolekyylinen normaalien ja kasvainsolujen trail-geenin indusointi syöpähoitona
Mitra et al. Novel delivery approaches for cancer therapeutics
Yang et al. BRD4: An emerging prospective therapeutic target in glioma
Li et al. Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma
KR102490334B1 (ko) 암 치료용 아젤니디핀 약학 조성물의 새로운 적응증
Shen et al. A novel and promising therapeutic approach for NSCLC: recombinant human arginase alone or combined with autophagy inhibitor
Zhang et al. Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: in vitro and in vivo
Mégalizzi et al. 4-IBP, a σ1 receptor agonist, decreases the migration of human cancer cells, including glioblastoma cells, in vitro and sensitizes them in vitro and in vivo to cytotoxic insults of proapoptotic and proautophagic drugs
US9242000B2 (en) Micro-RNAs and micro-RNA inhibitors to modulate blood vessel growth, patterning, tumor growth and malignant disease and method for making and using them
Hussain et al. Autophagy‐associated non‐coding RNAs: Unraveling their impact on Parkinson's disease pathogenesis
Kim et al. NVP-BEZ-235 enhances radiosensitization via blockade of the PI3K/mTOR pathway in cisplatin-resistant non-small cell lung carcinoma
JP2014526456A5 (https=)
RU2014119150A (ru) Модулирование некоторых тирозинкиназ
JP2017506662A5 (https=)
HRP20191145T1 (hr) Postupak predviđanja ishoda liječenja s afliberceptom kod pacijenta za kojeg se sumnja da ima rak
Viktorsson et al. Advances in molecular targeted therapies to increase efficacy of (chemo) radiation therapy
Gao et al. Berberine enhances gemcitabine-induced cytotoxicity in bladder cancer by downregulating Rad51 expression through inactivating the PI3K/Akt pathway
Tian et al. Inhibition of YAP sensitizes the selumetinib treatment for neurofibromatosis type 1 related plexiform neurofibroma
Hatakeyama et al. Synergistic effects of pemetrexed and amrubicin in non-small cell lung cancer cell lines: Potential for combination therapy
Botrous et al. Artemisinin pre-treatment fore cisplatin dosage enhances high grade urothelial carcinoma treatment in male albino mice via reverse gene expression modulation of FGFR3, HRAS, P53 and KDM6A
Li et al. AAZ2 induces mitochondrial-dependent apoptosis by targeting PDK1 in gastric cancer
CN105744958A (zh) 新颖医药组成物及其用途
IL266293B (en) Combinations of fgfr4 inhibitors and bile acid sequestrants
S. Jabir et al. The ferroptosis-ncRNA-exosome triad: key orchestrators in cancer immunopathogenesis
Nosaki et al. Safety of alectinib in non-small cell lung cancer patients with RET fusion gene (ALL-RET): Results from the dose-finding portion of a phase 1/2 study